The September HERU Policy Brief on self-monitoring for people receiving long-term vitamin K antagonist (Warfarin) therapy is available for download.
The September Policy Brief is produced from work on the 'Self-monitoring coagulation status in vitamin K antagonist therapy' project which recommended that self-monitoring is a safe and cost-effective option for individuals receiving long-term vitamin K antagonist therapy who have atrial fibrillation or an artificial heart valve.
Scotland, G. (2015) 'Is self-monitoring a cost-effective option for people receiving long-term vitamin K antagonist (Warfarin) therapy?', HERU Policy Brief, University of Aberdeen, September 2015.